Hypercalcitoninaemia in Patients with Pheochromocytoma

Overview

Journal Klin Wochenschr

Specialty General Medicine

Date 1978 Jul 15

PMID 672141

Citations 3

Authors

F Raue

J M BAYER

K H Rahn

C Herfarth

H Minne

R Ziegler

Affiliations

Soon will be listed here.

Abstract

As pheochromocytoma sometimes is accompanied by medullary thyroid carcinoma (in the sense of multiple endocrine adonomatosis type II = Sipple-Syndrome), serum calcitonin (CT) was measured by radioimmunoassay in 4 patients with pheochromocytoma. Before extirpation of the adreno-medullary tumor, serum CT was distinctly increased to 3 and 30 ng/ml in 2 of 4 patients, respectively. After removal of the tumor, serum CT was normal in the patients and pentagastrin stimulation produced no exaggerated CT response. In hydrochloric acid extracts from the two corresponding pheochromocytoma tissues, immunoreactive-Calcitonin (IR-CT) was detected, the concentrations amounting 1 and 4 ng/mg wet tissue. These findings suggest that hypercalcitonism in patients with pheochromocytoma cannot always be ascribed to the thyroid, i.e. increased calcitonin levels do not necessarily indicate a medullary carcinoma of this organ.

Citing Articles

Importance of early diagnosis and follow-up in multiple endocrine neoplasia (MEN II B).

Frank K, Raue F, Gottswinter J, Heinrich U, Meybier H, Ziegler R Eur J Pediatr. 1984; 143(2):112-6.

PMID: 6394335 DOI: 10.1007/BF00445797.

Immunohistochemical study of pheochromocytomas. An investigation of methionine-enkephalin, vasoactive intestinal peptide, somatostatin, corticotropin, beta-endorphin, and calcitonin in 16 tumors.

Hassoun J, Monges G, Giraud P, Henry J, Charpin C, PAYAN H Am J Pathol. 1984; 114(1):56-63.

PMID: 6140850 PMC: 1900405.

The importance of multiple endocrine neoplasia syndromes in differential diagnosis.

Schaaf L, Greschner M, GEISSLER W, Eckert B, SEIF F, Usadel K Klin Wochenschr. 1990; 68(13):669-72.

PMID: 1974310 DOI: 10.1007/BF01667014.

References

Steiner A, Goodman A, Powers S . Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore). 1968; 47(5):371-409. DOI: 10.1097/00005792-196809000-00001. View

Coombes R, Hillyard C, Greenberg P, MacIntyre I . Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet. 1974; 1(7866):1080-3. DOI: 10.1016/s0140-6736(74)90557-1. View

Raue F, Minne H, Schafer D, Ziegler R . [The determination of calcitonin for hospital use (author's transl)]. MMW Munch Med Wochenschr. 1977; 119(7):219-24. View

Deftos L, Bury A, Habener J, Singer F, Potts Jr J . Immunoassay for human calcitonin. II. Clinical studies. Metabolism. 1971; 20(12):1129-37. DOI: 10.1016/0026-0495(71)90038-2. View

Pearson K, Wells S, KEISER H . Familial medullary carcinoma of the thyroid, adrenal pheochromocytoma and parathyroid hyperplasia. A syndrome of multiple endocrine neoplasia. Radiology. 1973; 107(2):249-56. DOI: 10.1148/107.2.249. View

Sizemore G, Go V . Stimulation tests for diagnosis of medullary thyroid carcinoma. Mayo Clin Proc. 1975; 50(2):53-6. View

Kaplan E, Arnaud C, Hill B, PESKIN G . Adrenal medullary calcitonin-like factor: a key to multiple endocrine neoplasia, type 2?. Surgery. 1970; 68(1):146-9. View

Moseley J, Matthews E, Breed R, Galante L, Tse A, MacIntyre I . The ultimobranchial origin of calcitonin. Lancet. 1968; 1(7534):108-10. DOI: 10.1016/s0140-6736(68)92720-7. View

Greenfield B . Letter: Plasma-calcitonin and non-thyroid tumours. Lancet. 1974; 2(7873):164. DOI: 10.1016/s0140-6736(74)91595-5. View

10.

Milhaud G, Calmette C, Taboulet J, Julienne A, Moukhtar M . Letter: Hypersecretion of calcitonin in neoplastic conditions. Lancet. 1974; 1(7855):462-3. DOI: 10.1016/s0140-6736(74)92428-3. View

11.

Deftos L . Radioimmunoassay for calcitonin in medullary thyroid carcinoma. JAMA. 1974; 227(4):403-6. View

12.

Wells Jr S, ONTJES D, Cooper C, Hennessy J, Ellis G, McPHERSON H . The early diagnosis of medullary carcinoma of the thyroid gland in patients with multiple endocrine neoplasia type II. Ann Surg. 1975; 182(4):362-70. PMC: 1343993. DOI: 10.1097/00000658-197510000-00002. View

13.

Pearse A . The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem. 1969; 17(5):303-13. DOI: 10.1177/17.5.303. View

14.

Hennessy J, Gray T, Cooper C, ONTJES D . Stimulation of thyrocalcitonin secretion by pentagastrin and calcium in 2 patients with medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1973; 36(1):200-3. DOI: 10.1210/jcem-36-1-200. View

15.

Silva O, Becker K, Primack A, DOPPMAN J, Snider R . Ectopic secretion of calcitonin by oat-cell carcinoma. N Engl J Med. 1974; 290(20):1122-4. DOI: 10.1056/NEJM197405162902007. View

16.

VOELKEL E, TASHJIAN Jr A, DAVIDOFF F, Cohen R, PERLIA C, Wurtman R . Concentrations of calcitonin and catecholamines in pheochromocytomas, a mucosal neuroma and medullary thyroid carcinoma. J Clin Endocrinol Metab. 1973; 37(2):297-307. DOI: 10.1210/jcem-37-2-297. View

17.

Pearse A, Polak J . Endocrine tumours of neural crest origin: neurolophomas, apudomas and the APUD concept. Med Biol. 1974; 52(1):3-18. View

18.

DIETRICH F, Hunziker W, Fischer J . Synthetic human calcitonin: analysis of antibodies obtained from various animal species and determination of immunoreactive hormone in human sera. Acta Endocrinol (Copenh). 1975; 80(3):465-86. DOI: 10.1530/acta.0.0800465. View

19.

Hillyard C, Coombes R, Greenberg P, Galante L, MacIntyre I . Calcitonin in breast and lung cancer. Clin Endocrinol (Oxf). 1976; 5(1):1-8. View

20.

PALOYAN E, Scanu A, STRAUS F, PICKLEMAN J, Paloyan D . Familial pheochromocytoma, medullary thyroid carcinoma, and parathyroid adenomas. JAMA. 1970; 214(8):1443-7. View